Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Generic drug maker Teva Pharmaceuticals, Astellas Pharma subsidiary OSI Pharmaceuticals, Genentech, a member of the Roche Group, and Pfizer have settled a pending patent-infringement lawsuit over lung cancer drug Tarceva (erlotinib hydrochloride).
Subscribe to our email newsletter
Tarceva is prescribed for patients with advanced-stage non-small cell lung cancer (NSCLC) whose cancer has not spread or grown after initial treatment with certain types of chemotherapy (maintenance treatment) / after receiving at least 1 chemotherapy regimen (2nd/3rd-line treatment).
Reportedly, OSI, Genentech and Pfizer filed a case against Teva on 19 March 2009 with regard to US Patent Nos. 6,900,221, RE 41,065 and 7,087,613 for Tarceva tablets.
As a result, the case against Teva will be terminated by a Consent Order of Dismissal.